Cassava Sciences and two former executives are facing charges from the SEC for misleading claims about an Alzheimer’s drug candidate. The company has agreed to pay fines, and the charges include allegations of misleading claims and failure to disclose important information related to a mid-stage trial of the drug. Former CEO Remi Barbier and former senior vice president Lindsay Burns were also charged. The SEC claims that Cassava and Burns did not disclose crucial information about the trial samples and analysis, and that data was hand-picked to make the drug appear more effective. The resignations of top leaders have brought to light unethical practices in the Alzheimer’s disease world.
Source link
Cassava Sciences and former execs agree to SEC fines
